Plant Extracts in Hyperoxaluria Treatment: A Review of Experimental and Clinical Research

Stepanova, N.

doi:10.14744/ejmo.2019.92451

Cited by 3 publications

(8 citation statements)

References 45 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Як відомо, концентрація ОК в плазмі визначається балансом між надходженням оксалату з їжею, кишковою секрецією і адсорбцією, ендогенною продукцією та нирковою екскрецією [14,15]. Надходження ОК до клітин організму регулюють молекулярні механізми.…”

Section: король лесяunclassified

“…Надходження ОК до клітин організму регулюють молекулярні механізми. Більшість біологічних мембран є проникними для ОК, серед них еритроцити, клітини ниркового і кишкового епітелію [1,4,[14][15][16].…”

Section: король лесяunclassified

See 1 more Smart Citation

Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients

Korol

Stepanova

Vasylchenko

et al. 2021

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

The present study aimed to evaluate the changes in oxidative stress markers according to the concentration of plasma oxalic acid (POx) in end-stage renal disease (ESRD) patients. Methods. We conducted a cross-sectional observational study involving 72 ESRD patients and 30 relatively healthy individuals who served as a control reference group for evaluation of POx concentration. Among ESRD patients there were 32 hemodialysis (HD) patients and 40 peritoneal dialysis (PD). POx concentration was measured spectrophotometrically using a commercially available kit (MAK315, Sigma, Spain). Malonic dialdehyde (MDA), ceruloplasmin (CP), transferrin (TR), sulfhydryl groups (SH-groups), antioxidant blood capacity (AOC) and total peroxidase activity of erythrocytes (TPA) were measured and the oxidative stress index (OSI) was calculated in all examined patients. Results. A significant increase in POx concentration was observed in ESRD patients compared with healthy volunteers (p < 0.0001). The concentrations of MDA in serum, OSI in erythrocytes and serum of the examined patients were gradually increased, while serum levels of CP, AOC, SH-groups and TPA in erythrocytes, on the contrary, were decreased in accordance with the increasing trend of POx concentrations. Correlation analysis demonstrated a statistically significant direct relationship between POx concentration and MDA (r = 0.57; p <0.0001) and OSI (r = 0.64; p <0.0001). The inverse correlation was determined between POx and antioxidant markers: CP (r = -0.35; p = 0.007), SH-groups in serum (r = -0.3; p = 0.04) and erythrocytes (r = -0.53 ; p <0.0001). Conclusions. The intensity of oxidative-antioxidant balance disorders in the blood of ESRD patients has been associated with the POx concentration: the higher the concentration of POx was the more active oxidative processes and the more pronounced lack of antioxidant protective factors occurred. Further studies are needed to determine the role of POx in the initiation of oxidative stress and chronic inflammation in ESRD patients.

show abstract

Section: король лесяunclassified

Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients

Korol

Stepanova

Vasylchenko

et al. 2021

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

show abstract

“…Less kidney stone formation was found with the use of Dolichos biflorus [11]. In a study (47 patients took part in this trial), there was a significant reduction in the size of the kidney stones in comparison with potassium citrate after 6 months in the patients who used Dolichos biflorus [12]. Dolichos biflorus reduced inflammation by reducing the activity of cyclooxygenase, lipoxygenase, nitric oxide synthase, myeloperoxidase, and the amount of malondialdehyde (p < 0.05).…”

Section: Dolichos Biflorus (Horse Gram)mentioning

confidence: 90%

“…In a prospective, randomized, double-blind, placebo-controlled study, Crataeva nurvala had prospects for kidney stone treatment because it dissolved oxalate concretions and anesthetized their passage [16].…”

Section: Crataeva Nurvala (Varuna Bark)mentioning

confidence: 99%

See 1 more Smart Citation

Kidney stone risk reduction and size reduction utilizing medical plants

Blake¹,

Blake²

2022

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Kidney stones are not only a widespread problem now, but have been for centuries. Many of the plants used historically have now been found to be effective in reducing risk and reducing stone size in modern clinical trials. Both reducing stone size and reducing recurrence of stones after removal are important. Certain medical plants have been shown to slow the formation of calcium oxalate crystals. Several of these medical plants also have antioxidant and antimicrobial effects. The plants with the best clinical trials and supporting preclinical data showing effectiveness in reducing kidney stone formation and recurrence are Nigella sativa (black cumin seed), Dolichos biflorus (horse gram), Crataeva nurvala (varuna bark), and Tribulus terrestris (Gokshura). Some of these medical plants have been compared to tamsulosin (Flomax®) and potassium citrate for safety and effectiveness. Reviewed here are 11 medical plants with good clinical data, as well as 24 more plants with preclinical data or historical use.

show abstract

Enzyme-based color bar-style lateral flow strip for equipment-free and semi-quantitative determination of urinary oxalate

Huang

Zhou

Wang

et al. 2023

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

Plant Extracts in Hyperoxaluria Treatment: A Review of Experimental and Clinical Research

Cited by 3 publications

References 45 publications

Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients

Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients

Kidney stone risk reduction and size reduction utilizing medical plants

Enzyme-based color bar-style lateral flow strip for equipment-free and semi-quantitative determination of urinary oxalate

Contact Info

Product

Resources

About